A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia

Cancer Prevention Research

Volumn 9, Issue 12, 2016, Pages 906-914

  Lam, Stephen ^a   Mandrekar, Sumithra J ^b   Gesthalter, Yaron ^c   Allen Ziegler, Katie L ^b   Seisler, Drew K ^b   Midthun, David E ^b   Mao, Jenny T ^d   Aubry, Marie Christine ^b   McWilliams, Annette ^e   Sin, Don D ^f   Shaipanich, Tawimas ^a   Liu, Gang ^c   Johnson, Evan ^c   Bild, Andrea ^g   Lenburg, Marc E ^c   Ionescu, Diana N ^a   Mayo, John ^h   Yi, Joanne ^b   Tazelaar, Henry ^b   Harmsen, William S ^b   Smith, Judith ⁱ   Spira, Avrum E ^c   Beane, Jennifer ^c   Limburg, Paul J ^b   Szabo, Eva ⁱ   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MAYO CLINIC   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d New Mexico Veterans Affairs (VA) Healthcare System   (United States)

^e FIONA STANLEY HOSPITAL   (Australia)

^f ST PAUL S HOSPITAL   (Canada)

^g UNIVERSITY OF UTAH   (United States)

^h VANCOUVER GENERAL HOSPITAL   (Canada)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUTATHIONE; INOSITOL; INTERLEUKIN 6; KI 67 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SURFACTANT PROTEIN D; GLUCOSE; TUMOR MARKER; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; BRONCHIAL DYSPLASIA; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS DISEASE; BRONCHUS MUCOSA; CANCER PREVENTION; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPLASIA; ENZYME ACTIVITY; FAINTNESS; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; LUNG LAVAGE; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY EPITHELIUM; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENCE IMAGING; GENETICS; HYPERPLASIA; LUNG TUMOR; METABOLISM; METAPLASIA; MIDDLE AGED; PATHOLOGY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

AGED; BIOMARKERS, TUMOR; BIOPSY; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE; HUMANS; HYPERPLASIA; INOSITOL; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; METAPLASIA; MIDDLE AGED; OPTICAL IMAGING; PHOSPHATIDYLINOSITOL 3-KINASES; SMOKING; TOMOGRAPHY, SPIRAL COMPUTED; VITAMIN B COMPLEX;

EID: 85008423171     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0254     Document Type: Article

References (36)

1. Stewart BW, Wild CP, editors. The World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996;78:1004-10.
4. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-9.
5. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
6. Szabo E, Mao JT, Lam S, Reid ME, Keith RL. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e40S-60S.
7. Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 1993;14:1975-7.
8. Wattenberg LW, Estensen RD. Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res 1996;56:5132-5.
9. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra5.
10. Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006;15:1526-31.
11. Lam S, Kennedy T, Unger M, Miller YE, Gelmont D, Rusch V, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998;113:696-702.
12. Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Szabo E, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-11.
13. Lam S, Leriche JC, Kijek K, Phillips D. Effect of bronchial lavage volume on cellular and protein recovery. Chest 1985;88:856-9.
14. Travis W. Histological typing of lung and pleural tumors. Berlin-Heidelberg, Germany: Springer-Verlag; 1999.
15. McWilliams A, Mayo J, MacDonald S, leRiche JC, Palcic B, Szabo E, et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003;168:1167-73.
16. McWilliams AM, Mayo JR, Ahn MI, MacDonald SL, Lam SC. Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy. J Thorac Oncol 2006;1:61-8.
17. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffinembedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
18. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011; 12:323.
19. Wang L, Wang S, Li W. RSeQC:quality control of RNA-seq experiments. Bioinformatics 2012;28:2184-5.
20. Kusko RL, Brothers Ii JF, Tedrow J, Pandit K, Huleihel L, Perdomo C, et al. Integrated genomics reveals convergent transcriptomic networks underlying COPD and IPF. Am J Respir Crit Care Med. 2016 Apr 22. [Epub ahead of print].
21. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40.
22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
23. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014;15:R29.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
25. Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-9.
26. Lam S, Xu X, Parker-Klein H, Le Riche JC, Macaulay C, Guillaud M, et al. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. Int J Oncol 2003;23:1607-13.
27. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
28. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
29. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 2011;4:793-802.
30. Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila) 2009;2: 370-6.
31. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev 2010;29:5-14.
32. JeremyGeorge P, Banerjee AK, Read CA, O'Sullivan C, FalzonM, Pezzella F, et al. Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax 2007;62:43-50.
33. Lam S, Szabo E. Preinvasive endobronchial lesions: lung cancer precursors and risk markers? Am J Respir Crit Care Med 2015;192:1411-3.
34. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014;84:13-22.
35. Jen R, LamS. Detection and treatment of preneoplastic lesions. In: Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH, editors. Lung cancer. 4th ed. Hoboken, NJ: John Wiley & Sons, Inc. ; 2014. Chapter 7.
36. Pinsky PF, Nath PH, Gierada DS, Sonavane S, Szabo E. Short-and longterm lung cancer risk associated with noncalcified nodules observed on low-dose CT. Cancer Prev Res (Phila) 2014;7:1179-85.